tuberculosis tb remain serious health problem worldwide urgent need exist improv replace avail vaccine mycobacterium kovi bacillu calmettegu√©rin big vaccine protocol adapt two three dose induce longterm last immune previous studi show name dna encode tripleantigen fusion tfp rvcmtbrvc induce robust cellular immune response accompany four incl mycobacteria infect howe number compliance issue exist area lack appropri medic infrastructure multiple administer novel vehicular stat virus express vs develop elicit value observe entrants delivery potent antigenspecif cell response follow single dose office control bacteria growth level fold lower mock group week postinfect bcginfect mouse importantly immune provide protect compare receive p immune increase memory cell also spleen vsvvaccin could potent meghan assoc protect find support use antigen vector develop 